Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
NCT ID: NCT01031277
Last Updated: 2011-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2009-11-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Primary/secondary prevention patients.
* Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:
* Primary/secondary prevention patients.
* Patients with metabolic syndrome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
NCT01025388
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
NCT01604733
Pan-European Survey on the Under Treatment of Hypercholesterolemia
NCT00542867
National Survey on Dyslipidemic Patients
NCT00701402
Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
NCT01265836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
* Subject must sign informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinart International
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Gulf States
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof. Wael Al Mahmeed
Role: STUDY_CHAIR
Shaikh Khalifa Medical City
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Abu Dhabi, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shehab A, Al-Rasadi K, Arafah M, Al-Hinai AT, Al Mahmeed W, Bhagavathula AS, Al Tamimi O, Al Herz S, Al Anazi F, Al Nemer K, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Al Jassim O, Al Hallaq O, Baslaib FOAS, Alawadhi M, Amin H, Al-Hashmi K, Oulhaj A. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings. Curr Vasc Pharmacol. 2018;16(4):368-375. doi: 10.2174/1570161115666170705153815.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SRP-CB-CRE-2006/01
Identifier Type: -
Identifier Source: secondary_id
NIS-GU-CRE-2009/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.